LSL Pharma Group Inc. LSL.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.57M | 8.97M | 5.25M | 5.50M | 5.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.57M | 8.97M | 5.25M | 5.50M | 5.22M |
| Cost of Revenue | 9.31M | 8.41M | 5.02M | 3.81M | 3.73M |
| Gross Profit | 1.26M | 560.60K | 233.10K | 1.69M | 1.49M |
| SG&A Expenses | 1.74M | 1.84M | 1.76M | 1.30M | 1.10M |
| Depreciation & Amortization | 317.20K | 61.20K | -291.90K | 103.10K | 166.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.36M | 10.30M | 6.49M | 5.21M | 5.00M |
| Operating Income | -796.20K | -1.34M | -1.23M | 286.10K | 219.70K |
| Income Before Tax | -1.62M | -2.05M | -832.80K | -856.70K | -281.20K |
| Income Tax Expenses | -- | -- | -46.60K | -- | -- |
| Earnings from Continuing Operations | -1.62M | -2.05M | -786.20K | -856.70K | -281.20K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.62M | -2.05M | -786.20K | -856.70K | -281.20K |
| EBIT | -796.20K | -1.34M | -1.23M | 286.10K | 219.70K |
| EBITDA | -19.50K | -742.80K | -1.12M | 726.00K | 730.70K |
| EPS Basic | -0.01 | -0.02 | -0.01 | -0.01 | 0.00 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.02 | -0.01 | -0.01 | 0.00 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 126.73M | 126.73M | 121.80M | 117.57M | 115.53M |
| Average Diluted Shares Outstanding | 126.73M | 126.80M | 121.80M | 117.57M | 115.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |